Evaluation of the Validity of SAMe-TTR Score in a Cohort of Venous Thromboembolism Patients Treated With Warfarin

• Main Authors: Eman Nawash Alhmoud MSc, BCPS, CPHQ, Hazem Elewa RPh, PhD, BCPS, Mohammed S. Abdul Gelil RPh, MSc, Osama B. Abd El Samad MSc, Abdelnasser Y. Elzouki MD, MSc, PhD
• Format: Article
• Language: English
• Published: SAGE Publishing 2020-09-01
• Series: Clinical and Applied Thrombosis/Hemostasis
• Online Access: https://doi.org/10.1177/1076029620945039

Low SAMe-TT 2 R 2 score of <2 was validated as a predictor of optimum anticoagulation control, reflected by mean time in therapeutic range (TTR) above 65% to 70%, among warfarin-treated atrial fibrillation patients. This study aimed to validate the ability of SAMe-TT 2 R 2 score and its individual components in predicting anticoagulation control (mean TTR and clinical events) among a cohort of venous thromboembolism (VTE) patients in Qatar. A total of 295 patients were retrospectively evaluated. There was a trend toward statistical significance in mean TTR between low (<2) and high (≥ 2) SAMe-TT 2 R 2 score groups ( P = .05), a difference that was not sustained when a cutoff of 3 was used (ie, a score of 3 or more). Patients with poor INR control (TTR <70%) were numerically less likely to have SAMe-TT 2 R 2 score of <2 compared with those with good INR control, though the difference was not statistically significant (16.7% vs 83.3%, respectively, P = .4). No thromboembolic events were reported, and no association was found between the score and risk of bleeding. Non-Caucasian origin was the only significant predictor of good anticoagulation in the studied cohort. In conclusion, SAMe-TT 2 R 2 score could not predict quality of anticoagulation control in a cohort of VTE patients treated with warfarin in Qatar. Contribution of other clinical factors and whether a different scoring may yield better prediction of anticoagulation control remains to be tested.